Abstracts tagged "Biologicals"

Abstract Number: 2662 • ACR Convergence 2025
Target trial emulation of biologic and targeted synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis-associated interstitial lung disease
Gregory McDermott¹, Daniel Solomon², Jeffrey Sparks³ and Rishi Desai³, ¹Brigham and Women's Hospital, Brookline, MA, ²Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA, ³Brigham and Women's Hospital, Boston, MA
Background/Purpose: RA-ILD is associated with high mortality, but the optimal treatment approach is unclear. While immunosuppressants may treat inflammatory components of ILD, there are concerns…
Abstract Number: 0180 • ACR Convergence 2025
Digital Transformation in IMID Care: Results from the Implementation of IMIDOC
JOSE INIESTA-CHAMORRO¹, Marta Novella-Navarro², Diego Benavent³, HELENA BORREL-PAÑOS⁴, Xabier Michelena Vegas⁵, Javier Bachiller⁶, Verónica García García⁷, ESTHER ESPARTAL⁴, LETICIA LOJO-OLIVEIRA⁸, Enrique Calvo-Aranda⁹, José Rodríguez gago¹⁰, Gema Bonilla¹¹, Irene Monjo Henry², Victoria Navarro-Compan¹², Jaime Arroyo¹⁰, Eugenio de Miguel², Mariana Díaz-Almirón¹³, cARMEN ALEGRE¹⁰, ENRIQUE J GÓMEZ¹⁴ and Chamaida Plasencia-Rodríguez², ¹¹Biomedical Engineering and Telemedicine Centre, ETSIT, Center for Biomedical Technology, Universidad Politéctica de Madrid, TELEMEDICINE, MADRID, ²Hospital Universitario La Paz, Madrid, Spain, ³Hospital Universitari de Bellvitge, Madrid, Spain, ⁴⁴HOSPITAL UNIVERSITARIO VALL D´HEBRON, RHEUMATOLOGY, BARCELONA, Spain,, BARCELONA, ⁵Hospital Universitari Vall Hebron, Barcelona, Spain, ⁶Hospital Ramon y Cajal, Madrid, Madrid, Spain, ⁷Ramón y Cajal University Hospital, MADRID, Spain, ⁸Hospital Universitario Infanta Leonor, Madrid, Spain, ⁹Department of Rheumatology, Hospital Universitario Infanta Leonor / Universidad Complutense de Madrid, Madrid, Spain, madrid, ¹⁰Hospital Universitario La Paz, MADRID, ¹¹Hospital Universitario La Paz, Rheumatology, Madrid, Madrid, Spain, ¹²Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ¹³LIMA, Advanced Medical Informatics Lab, La Paz Research Institute, IdiPAZ, Madrid, Spain, ¹⁴¹Biomedical Engineering and Telemedicine Centre, ETSIT, Center for Biomedical Technology, Universidad Politéctica de Madrid, TELEMEDICINE, MADRID, Spain,, MADRID
Background/Purpose: Rheumatoid arthritis (RA) and spondyloarthritis (SpA) are immune-mediated inflammatory diseases (IMIDs) characterized by joint and spinal inflammation, leading to functional impairment. Their management requires…
Abstract Number: 0484 • ACR Convergence 2025
Comparable Efficacy of FK-Tocilizumab and Reference Tocilizumab in Rheumatoid Arthritis Patients With and Without Prior Biologic Exposure
Ernest Choy¹, Marco Gattorno², Kamila Klama³, Andras Illes⁴, Peter Baker⁵, Maria Romanova Michailidi⁶ and Anna Zubrzycka-Sienkiewicz⁷, ¹Division of Infection and Immunity, CREATE Centre, Cardiff University, Cardiff, United Kingdom, ²IRCCS G. Gaslini, Genova, Genoa, Italy, ³Solumed Clinical Research Center, Poznan, Poland, ⁴Fresenius Kabi SwissBioSim, Eysin, Switzerland, ⁵Fresenius Kabi Biopharma, Eysins, Switzerland, ⁶University of Geneva, Eysins, Switzerland, ⁷Reumatika - Centrum Reumatologii, Warszawa, Poland
Background/Purpose: Biosimilars offer comparable efficacy and safety to their originators, thereby improving patient access to affordable treatments. FK-Tocilizumab (FK-toci) is the first tocilizumab biosimilar approved…
Abstract Number: 0803 • ACR Convergence 2025
Improved Efficacy and Safety Outcomes in Patients with SLE Treated with Belimumab (BEL) Versus Immunosuppressants (IS), in Addition to Antimalarials (AM) and Glucocorticoids (GC): A Post Hoc Summary of Five Phase 3 Trials
Mariele Gatto¹, Karen H. Costenbader², Andreas Schwarting³, Julia Harris⁴, Ciara O'Shea⁵, Roger A. Levy⁶ and Andrea Doria⁷, ¹Academic Rheumatology Centre, Department of Clinical and Biological Sciences, University of Turin, Mauriziano Hospital, Turin, Italy, ²Harvard Medical School and Brigham and Women's Hospital, Boston, MA, ³Johannes Gutenberg University Mainz, University Medical Centre, Mainz, Germany, ⁴GSK, Biostatistics, London, United Kingdom, ⁵Global Medical Affairs, GSK, Dublin, Ireland, ⁶GSK, Specialty Care, Global Medical Affairs, Collegeville, PA, ⁷University of Padova, Padova, Italy
Background/Purpose: Chronic GC and IS use increases damage accrual and mortality. The 2023 EULAR SLE recommendations support initiation of biologics such as BEL, a human…
Abstract Number: 0588 • ACR Convergence 2025
The effect of biological and targeted synthetic DMARDs on peripheral manifestations in axial spondyloarthritis: a systematic literature review
Casper Webers¹, AUGUSTA ORTOLAN², Elena Nikiphorou³, Alexandre Sepriano⁴, Louise Falzon⁵, Clementina López Medina⁶, Dafne capelusnik⁷, Désirée Van Der Heijde⁸, Anna Molto⁹ and Sofia Ramiro¹⁰, ¹Maastricht University Medical Centre, Maastricht, Netherlands, ²Policlinico Universitario Agostino Gemelli IRCSS, Rome, Italy, ³King's College London, London, United Kingdom, ⁴Department of Rheumatology, Leiden University Medical Centre, Portela Loures, Portugal, ⁵Sheffield Centre for Health and Related Research, University of Sheffield, Sheffield, United Kingdom, ⁶Department of Medicine, Hospital Universitario Reina Sofia, University of Cordoba, IMIBIC, Cordoba, Spain, ⁷Tel Aviv Sourasky Medical Center, Ramat Gan, Israel, ⁸Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁹Assistance Publique Hôpitauxde Paris, Paris, France, ¹⁰Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: In axial spondyloarthritis (axSpA), peripheral musculoskeletal manifestations (peripheral arthritis, enthesitis, dactylitis) are common and contribute to the burden of disease. Our objective was to…
Abstract Number: 1090 • ACR Convergence 2025
Quantitative Immunoglobulin Screening Prior to Rituximab Initiation: A Retrospective Cohort Study
Amelia Khoo and Anokhi Saklecha, Yale University, New Haven, CT
Background/Purpose: Rituximab, a monoclonal antibody which binds to the CD20 antigen of B cells, is used in the treatment of many rheumatologic conditions. Due to…
Abstract Number: 1312 • ACR Convergence 2025
Evolution of patients with active rheumatoid arthritis: analysis of disease activity trajectories in a tertiary‑care rheumatology department
Elodie Portier¹, Olivier Fogel², Terkia Medkour³, Sophie Hecquet³ and Jérôme AVOUAC³, ¹Rheumatology department, Bicetre hospital, Le Kremlin Bicetre, France, ²AP-HP, Paris, France, ³Rheumatology department, Cochin hospital, Paris, France
Background/Purpose: The objective of this study was to identify clusters of patients with rheumatoid arthritis (RA) in clinical practice, according to evolution of disease activity…
Abstract Number: 1446 • ACR Convergence 2025
Persistence of Second-line Treatment in Anti-TNF-experienced Axial Spondyloarthritis Patients: Comparing Cycling Anti–TNF vs Switching to a Different Mechanism of Action
José Miguel Senabre¹, Lucia Otero², Jerusalén Calvo³, Vega Jovaní⁴, Javier Manero-Ruiz⁵, Rabadán Elena⁶, Eugenia Enriquez⁷, Yanira Pérez⁸, Alicia Garcia⁹, Francisca Sivera¹⁰, Olga Martínez¹¹, María Colazo Burlato¹², Diana Sueiro¹³, Fernando Sánchez-Alonso¹⁴ and Isabel Castrejón Fernández¹⁵, ¹Hospital Marina Baixa, Villajoyosa/Vila Joiosa, La, Comunidad Valenciana, Spain, ²Spanish Society of Rheumatology, Madrid, Spain, ³IMIBIC / Reina Sofia Hospital / University of Cordoba, Córdoba, Spain, ⁴Hospital General Universitario de Alicante, Reumatología, Alicante, Alicante, Comunidad Valenciana, Spain, ⁵Hospital Miguel Servet, Zaragoza, Spain, ⁶Hospital Universitario Príncipe de Asturias, Alcala de Henares, Spain, ⁷Clínica Universidad de Navarra, Madrid, Spain, ⁸Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain, ⁹Rheumatologist, La Laguna, Spain, ¹⁰Hospital General Universitario Elda, Elda, Spain, ¹¹Hospital Universitario de Salamanca, Salamanca, Castilla y Leon, Spain, ¹²Hospital Universitario de Burgos, Burgos, Spain, ¹³Complexo Hospitalario Universitario de Ourense, Ourense, ¹⁴Sociedad Española de Reumatología, Madrid, Spain, ¹⁵MD, PhD, Madrid, Madrid, Spain
Background/Purpose: Failure of a first-line anti-TNF in axial spondyloarthritis (axSpA) is common, and when it occurs, there are no randomized clinical trials (RCTs) comparing the…
Abstract Number: 1548 • ACR Convergence 2025
Anifrolumab In Systemic Lupus Erythematosus. Spanish Multicenter Registry In Clinical Practice
Vanesa Calvo-Río¹, Carmen Secada-Gómez¹, Miriam Retuerto Guerrero², Judit Font-Urgelles³, Ivette Casafont-Solé³, Adrián Mayo-Juanatey⁴, Juan José Alegre-Sancho⁵, DALIFER FREITES⁶, Cristina Hormigos Martin⁷, Noemí Garrido⁸, GUILLERMO GONZALEZ ARRIBAS⁹, Juan Roberto Miguelez Sanchez¹⁰, Andrea García-Valle¹¹, Marta Ibañez¹², Fernando Lozano Morillo¹³, Ángel García Manzanares¹⁴, Sebastián Sandoval-Moreno¹⁵, Josefina Cortés-Hernández¹⁶, Deseada Palma-Sanchez¹⁷, LETICIA LOJO-OLIVEIRA¹⁸, Evelin Cervantes¹⁹, Paz Collado Ramos²⁰, cristina arciniega Larios²¹, Luis Sala²², Eztizen Labrador-Sánchez²³, Cilia Peralta-Ginés²⁴, Nahia Plaza-Aulestia²⁵, Irati Urionaguena Onaindia²⁶, Miguel Medina Malone²⁷, Jose Rosas Gómez de Salazar²⁸, Montserrat Corteguera²⁹, Laura Cebrian³⁰, Fred Anton Pages³¹, Jose Ramón Lamua-Riazuelo³², María Dolores Fábregas Canales³³, María José Alados Hernández³⁴, Marta Garijo Bufort³⁵, Anna Pamies³⁶, Luis Sarabia³⁷, Rodrigo Aguirre-del-Pino³⁸, José Ángel Cabezas Lefler³⁹, alvaro seijas³⁸, Carmen Carrasco-Cubero⁴⁰, Ana López-Cerón Cofiño⁴¹, Vera Ortiz-Santamaria⁴², Santos Castañeda⁴³, Maria Laino⁴⁴, Carmen Ordás Calvo⁴⁵, Celia arconada⁴⁶, ana Urruticoechea-Arana⁴⁷, Blanca Garcia-Magallon⁴⁸, Ana Valeria Acosta Alfaro⁴⁹, Samuel Leal Rodriguez⁵⁰, Marina Salido Olivares⁷, Patricia Lavilla Villar⁵¹, Anahy Maria Brandy³, Inmaculada Ros Vilamajo⁵², Alvaro García Martos⁵³, Berta Magallares⁵⁴, Guillen Sada Urmeneta⁵⁵, Cristina Córdoba Martín⁵⁶, Elena Riera Alonso⁵⁷, Carmen Bejerano-Herreria⁵⁸ and Ricardo Blanco,<58, ¹Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain, ²Complejo Asistencial Universitario de Leon, Leon, Castilla y Leon, Spain, ³Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ⁴Hospital Universitario Doctor Peset, Valencia, Comunidad Valenciana, Spain, ⁵Hospital Universitario Doctor Peset, Valencia, Spain, ⁶Rheumatology Service, San Carlos Clinical Hospital, Madrid, Madrid, Spain, ⁷Hospital Clínico San Carlos, Madrid, Spain, ⁸Hospital Universitario Virgen del Rocío, Sevilla, Andalucia, Spain, ⁹Facultativo especialista, PALMA DE MALLORCA, Galicia, Spain, ¹⁰Department of Rheumatology, Hospital Universtiario de Móstoles, Madrid, Spain, Madrid, Madrid, Spain, ¹¹Rheumatology. Hospital General Río Carrión, Palencia, Castilla y Leon, Spain, ¹²Hospital Universitario de la Santa Creu i Sant Pau, Barcelona, Catalonia, Spain, ¹³Hospital Central de La Defensa Gómez Ulla, Madrid, Madrid, Spain, ¹⁴Hospital Universitario de Torrevieja, Alicante, Spain, ¹⁵Hospital Universitario Vall D'Hebron, Barcelona, Spain, ¹⁶Hospital Universitari Vall d’Hebron-Universitat Autónoma de Barcelona, Barcelona, Spain, ¹⁷Rheumatology. Hospital Rafael Méndez, Lorca, Murcia, Spain, ¹⁸Hospital Universitario Infanta Leonor, Madrid, Spain, ¹⁹Hospital Provincial de Pontevedra, Pontevedra, Spain, ²⁰Department of Rheumatology, Hospital Universitario Severo Ochoa, Madrid, Spain,, MADRID, Madrid, Spain, ²¹Hospital de Mérida, Badajoz, Spain, ²²Hospital Universitario de Torrejón, Madrid, Spain, ²³Hospital General de La Rioja, Logroño, Spain, ²⁴Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain, ²⁵Hospital Galdakao, Vizcaya, Spain, ²⁶Rheumatology.Hospital Galdakao, Vizcaya, Pais Vasco, Spain, ²⁷Hospital de Calahorra, Calahorra, Spain, ²⁸Hospital Marina Baixa, PALMA DE MALLORCA, Spain, ²⁹Rheumatology. Complejo Asistencial de Ávila, Ávila, Castilla y Leon, Spain, ³⁰Department of Rheumatology, Hospital Universitario Infanta Leonor / Universidad Complutense de Madrid, Madrid, Spain, Madrid, Spain, ³¹Hospital General de Segovia, Segovia, Spain, ³²Hospital Universitario del Henares, Madrid, Spain, ³³Hospital de Barbastro, Huesca, Spain, ³⁴Hospital Universitario Puerta del Mar, Cadiz, Spain, ³⁵Hospital de Sagunto, Valencia, Spain, ³⁶Hospital Verge de la Cinta, Tortosa, Tarragona, Spain, ³⁷Complejo Hospitalario de Jaén, Jaén, Spain, ³⁸Hospital Universitario Lucus Augusti, Lugo, Spain, ³⁹Complejo Asistencial de Zamora, Zamora, Spain, ⁴⁰Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain, ⁴¹Hospital Santa Bárbara, Soria, Spain, ⁴²Hospital General de Granollers, Barcelona, Spain, ⁴³Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, ⁴⁴Hospital Universitario de Navarra, Pamplona, Spain, ⁴⁵Hospital Universitario de Cabueñes, Gijón, Spain, ⁴⁶Hospital universitario de Getafe, Getafe, Madrid, Spain, ⁴⁷Rheumatology Division. Hospital Universitario Son Espases, Palma de Mallorca, Spain, ⁴⁸Rheumatology, Hospital Universitario Puerta de Hierro, Madrid, Spain, ⁴⁹Hospital Universitario Infanta Sofia; Universidad Europea de Madrid; FIIB HUIS-HUHEN, Madrid, Spain, ⁵⁰Hospital Universitario La Fe, Valencia, Valencia, Spain, ⁵¹Hospital General de Villalba, Collado Villalba, Madrid, Spain, ⁵²Hospital Son Llàtzer, Palma de Mallorca, Spain, ⁵³Hospital del Tajo, Aranjuez, Madrid, Spain, ⁵⁴Hospital de Sant Pau, Barcelona, Spain, ⁵⁵Rheumatology, Hospital Reina Sofía, Tudela, Spain, ⁵⁶Hospital Universitario Nuestra Señora de la Candelaria, Santa Cruz de Tenerife, Tenerife, Spain, ⁵⁷Hospital Universitari Mùtua Terrassa, Terrassa, Spain, ⁵⁸Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain.

Background/Purpose: Anifrolumab (ANI) is a human monoclonal antibody that binds to the type I interferon receptor subunit 1 (IFNAR1). ANI was approved by Spanish authorities…
Abstract Number: 1992 • ACR Convergence 2025
Tolerance of Methotrexate Coadministered with Pegloticase in Patients with Uncontrolled Gout: Findings from MIRROR RCT
Vinicius Domingues¹, Alexis Woods², Xiaoqing Yang³, Brian Lamoreaux⁴ and Michael Weinblatt⁵, ¹Rheumatology, Allergy, Asthma & Arthritis Center, Daytona beach, FL, ²Amgen, Detroit, MI, ³Amgen, Seattle, WA, ⁴Amgen, Inc., Deerfield, IL, ⁵Brigham and Women's Hospital/ Harvard Medical School, Waban, MA
Background/Purpose: Methotrexate (MTX) coadministered with pegloticase attenuates anti-drug antibody formation, leading to higher response rates and markedly reduced infusion reaction risk compared with pegloticase +…
Abstract Number: 2299 • ACR Convergence 2025
Real-world clinical effectiveness of rituximab rescue therapy in patients with progressive interstitial lung disease associated with primary sjögren’s syndrome
Paula Estrada-Alarcón¹, Delia Reina², JUAN JOSE ALEGRE SANCHO³, Montserrat Roig Kim⁴, martí Aguilar-Coll⁵, Laia De Daniel Bisbe⁴, Aina Fabregat⁵, Monica Cubells⁵ and Javier Narváez⁶, ¹Hospital de San Juan Despí Moisès Broggi, Barcelona, Spain, ²Complex Hospitalari Universitari Moisès Broggi, Barcelona, Spain, ³Department of rheumatology. Hospital Universitario Doctor Peset, Valencia, Spain, ⁴Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain, ⁵Hospital Universitari de Bellvitge, Barcelona, Spain, ⁶Hospital Universitario de Bellvitge, Barcelona, Spain
Background/Purpose: To evaluate the real-world, long-term effectiveness of rituximab (RTX) as rescue therapy in patients with primary Sjögren’s syndrome-associated interstitial lung disease (pSS-ILD).Methods: Multicentre observational…
Abstract Number: 2453 • ACR Convergence 2025
Belimumab Is Associated with Lower Risk of Progression to LN Compared with Standard of Care in Patients with SLE
Maral DerSarkissian¹, Yan Chen¹, Ariel Chao¹, Shumin Rui¹, Bronwyn Moore², Karen Worley³, Daniel Moldaver⁴, Jeffrey J. Ellis³ and Aarat M Patel⁵, ¹Analysis Group, Los Angeles, CA, ²Analysis Group, Montreal, QC, Canada, ³GSK, Global Real-World Evidence & Health Outcomes Research, Collegeville, PA, ⁴GSK, Global Real-World Evidence & Health Outcomes Research, Toronto, ON, Canada, ⁵GSK, US Medical Affairs, Durham, NC
Background/Purpose: LN develops in ~40% of patients with SLE and is associated with increased risk of morbidity, including end-stage kidney disease, and mortality. Belimumab, a…
Abstract Number: 2669 • ACR Convergence 2025
RESET-Myositis: Clinical Trial Evaluating Rese-cel (Resecabtagene Autoleucel), A Fully Human, Autologous 4-1BB CD19-CAR T Cell Therapy in Idiopathic Inflammatory Myopathies
Erin Wilfong¹, Tahseen Mozaffar², Elie Naddaf³, Nizar Chahin⁴, Huifang Lu⁵, Iazsmin Bauer Ventura⁶, Courtney Little⁷, Carl diCasoli⁷, Claire Miller⁸, Jenell Volkov⁷, Daniel Nunez⁷, Thomas Furmanak⁷, Jason Stadanlick⁷, Larissa Ishikawa⁷, Zachary Vorndran⁷, Alexandra Ellis⁷, Jazmean Williams⁷, Steve Flanagan⁷, Quynh Lam⁸, Fatemeh Hadi-Nezhad⁸, Raj Tummala⁸, Samik Basu⁷ and David Chang⁹, ¹Vanderbilt University Medical Center, Nashville, TN, USA, Nashville, TN, ²University of California, irvine, Orange, CA, ³Mayo Clinic, Rochester, MN, ⁴Oregon Health & Science University, Portland, ⁵UT MD Anderson Cancer Center, Houston, TX, ⁶University of Chicago, Chicago, IL, ⁷Cabaletta Bio, Philadelphia, PA, ⁸Cabaletta Bio, Philadelphia, ⁹Cabaletta Bio, Bryn Mawr, PA
Background/Purpose: The goals of treatment for idiopathic inflammatory myopathy (IIM) are to eliminate or reduce inflammation, restore muscle performance, reduce morbidity, and improve a patient’s…
Abstract Number: 0194 • ACR Convergence 2025
Evaluation of a Home-based Therapeutics Service: Feasibility, Patient and Caregiver Experience, and Cost
Xiaohui Xin, Andrea Low, Sow Ling Yee, Miao Miao Liu, Christina Tan, Daphne Ng and Siaw Ing Yeo, Singapore General Hospital, Singapore, Singapore
Background/Purpose: The home-based therapeutics service (HTS) by a community nurse is part of an ongoing larger initiative—Community Therapeutics Programme (CTP)—spearheaded by the Rheumatology and Immunology…
Abstract Number: 0485 • ACR Convergence 2025
Multicenter study on the use of Upadacitinib: Results in RA patients previously treated with Baricitinib
Guillermo Gonzalez Mozo de Rosales¹, Luis Maria Lopez-Dominguez², Nerea Alcorta-Lorenzo³, oihane ibarguengoitia Barrena⁴, David Montero⁵, Ana Ruibal Escribano⁶, estibaliz barastay Alberdi⁷, Jesus Alejandro Valero Jaimes⁸, Libe Ibarrola⁹, Paula Garcia Escudero¹⁰, Marta Lopez I Gomez¹¹, Eva Galindez Aguirregoicoa¹² and Maria Luz Garcia Vivar¹³, ¹Basurto University Hospital, Bilbao, Spain, ²Rheumatology Department, Donostia University Hospital., San Sebastián, Pais Vasco, Spain, ³Rheumatology Department, Donostia University Hospital., San Sebastian, Spain, ⁴Galdakao-Usansolo University Hospital, GALDAKAO, Spain, ⁵Galdakao-Usansolo University Hospital, Bilbao, Spain, ⁶Urduliz Hospital, Urduliz, Pais Vasco, Spain, ⁷Urduliz Hospital, Urduliz, Spain, ⁸Hospital Bidasoa, Irán, Spain, ⁹Galdakao-Usansolo University Hospital, Galdakao, ¹⁰H.U.Araba, Vitoria, ¹¹Araba University Hospital, Vitoria, Pais Vasco, Spain, ¹²Basurto University Hospital, Bilbao, Pais Vasco, Spain, ¹³Basurto Hospital, Bilbao, Spain
Background/Purpose: Rheumathoid Arthritis (RA) is a chronic inflammatory disease that affects the musculoskeletal system. Early and effective treatment is important to improve the quality of…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].